Phase 2, Phase 3 Recruiting NIH
This phase II/III trial examines whether patients who have undergone surgical removal of bladder, kidney, ureter or urethra, but require an additional treatment called immunotherapy to help prevent their urinary tract (urothelial) cancer f…
Sponsor: National Cancer Institute (NCI)
NCT ID: NCT05987241
Sites in Texas: - UT Southwestern Simmons Cancer Center - RedBird — Dallas, Texas
- UT Southwestern/Simmons Cancer Center-Dallas — Dallas, Texas
- UT Southwestern/Simmons Cancer Center-Fort Worth — Fort Worth, Texas
- Lyndon Baines Johnson General Hospital — Houston, Texas
- Baylor College of Medicine/Dan L Duncan Comprehensive Cancer Center — Houston, Texas
Phase 3 Recruiting Academic/Other
This phase III trial compares the effect of adding tivozanib to standard therapy pembrolizumab versus pembrolizumab alone for the treatment of patients with high-risk renal cell carcinoma (RCC). Immunotherapy with monoclonal antibodies, su…
Sponsor: Alliance for Clinical Trials in Oncology
NCT ID: NCT06661720
Sites in Texas: - The Don and Sybil Harrington Cancer Center — Amarillo, Texas
- Houston Methodist San Jacinto Hospital — Baytown, Texas
- Houston Methodist Cypress Hospital — Cypress, Texas
- Parkland Memorial Hospital — Dallas, Texas
- UT Southwestern Simmons Cancer Center - RedBird — Dallas, Texas
Phase 3 Recruiting Network
This phase III trial compares the effect of adding surgery to a standard of care immunotherapy-based drug combination versus a standard of care immunotherapy-based drug combination alone in treating patients with kidney cancer that has spr…
Sponsor: SWOG Cancer Research Network
NCT ID: NCT04510597
Sites in Texas: - UT Southwestern Simmons Cancer Center - RedBird — Dallas, Texas
- UT Southwestern/Simmons Cancer Center-Dallas — Dallas, Texas
- UT Southwestern/Simmons Cancer Center-Fort Worth — Fort Worth, Texas
- Baylor College of Medicine/Dan L Duncan Comprehensive Cancer Center — Houston, Texas
- Ben Taub General Hospital — Houston, Texas
Phase 3 Recruiting Academic/Other
This phase III trial compares the effectiveness of fractionated stereotactic radiosurgery (FSRS) to usual care stereotactic radiosurgery (SRS) in treating patients with cancer that has spread from where it first started to the brain. Radia…
Sponsor: NRG Oncology
NCT ID: NCT06500455
Sites in Texas: - MD Anderson in The Woodlands — Conroe, Texas
- Baylor College of Medicine/Dan L Duncan Comprehensive Cancer Center — Houston, Texas
- M D Anderson Cancer Center — Houston, Texas
- Memorial Hermann Texas Medical Center — Houston, Texas
- MD Anderson West Houston — Houston, Texas
Phase 3 Recruiting Industry
The purpose of the study is to evaluate the progression-free survival (PFS) of casdatifan versus placebo when each is given in combination with cabozantinib in adult patients with confirmed advanced or metastatic clear cell Renal Cell Carc…
Sponsor: Arcus Biosciences, Inc.
NCT ID: NCT07011719
Sites in Texas: - Texas Tech University Health Science Center — Lubbock, Texas
Phase 3 Recruiting Industry
This is a randomized, Phase 3, double-blind, placebo-controlled study of pazopanib plus abexinostat versus pazopanib plus placebo in patients with locally advanced unresectable or metastatic renal cell carcinoma (RCC).
Sponsor: Xynomic Pharmaceuticals, Inc.
NCT ID: NCT03592472
Sites in Texas: - HOPE Cancer Center of East Texas — Tyler, Texas
Phase 3 Recruiting Industry
Researchers are looking for new ways to treat advanced solid tumors and von Hippel-Lindau (VHL)-related tumors: * Advanced means the cancer has spread to other parts of the body (metastatic) or cannot be removed with surgery * Solid tumors…
Sponsor: Merck Sharp & Dohme LLC
NCT ID: NCT07405164
Sites in Texas: - START San Antonio ( Site 0104) — San Antonio, Texas
Phase 2 Recruiting NIH
This phase II trial studies how well cabozantinib works in combination with nivolumab and ipilimumab in treating patients with rare genitourinary (GU) tumors that has spread from where it first started (primary site) to other places in the…
Sponsor: National Cancer Institute (NCI)
NCT ID: NCT03866382
Sites in Texas: - Saint Joseph Regional Cancer Center — Bryan, Texas
- UT Southwestern Simmons Cancer Center - RedBird — Dallas, Texas
- UT Southwestern/Simmons Cancer Center-Dallas — Dallas, Texas
- UT Southwestern/Simmons Cancer Center-Fort Worth — Fort Worth, Texas
- UT Southwestern Clinical Center at Richardson/Plano — Richardson, Texas
Phase 2 Recruiting Academic/Other
This phase II trial tests whether the addition of radiation to the primary tumor, typically given with stereotactic ablative radiation therapy (SABR), in combination with standard of care immunotherapy improves outcomes in patients with re…
Sponsor: NRG Oncology
NCT ID: NCT05327686
Sites in Texas: - Parkland Memorial Hospital — Dallas, Texas
- UT Southwestern Simmons Cancer Center - RedBird — Dallas, Texas
- UT Southwestern/Simmons Cancer Center-Dallas — Dallas, Texas
- UT Southwestern/Simmons Cancer Center-Fort Worth — Fort Worth, Texas
- UT Southwestern Clinical Center at Richardson/Plano — Richardson, Texas
Phase 2 Recruiting Network
This phase II trial studies how well combination chemotherapy works in treating patients with newly diagnosed stage II-IV diffuse anaplastic Wilms tumors (DAWT) or favorable histology Wilms tumors (FHWT) that have come back (relapsed). Dru…
Sponsor: Children's Oncology Group
NCT ID: NCT04322318
Sites in Texas: - Texas Tech University Health Sciences Center-Amarillo — Amarillo, Texas
- Dell Children's Medical Center of Central Texas — Austin, Texas
- Driscoll Children's Hospital — Corpus Christi, Texas
- Medical City Dallas Hospital — Dallas, Texas
- UT Southwestern/Simmons Cancer Center-Dallas — Dallas, Texas
Phase 1, Phase 2 Recruiting Industry
This study is testing a new medicine called PF-08634404 and how it works in adults with advanced Renal Cell Carcinoma (RCC)- a type of kidney cancer that is either locally advanced (spread to nearby tissues) or metastatic (spread to other …
Sponsor: Pfizer
NCT ID: NCT07227415
Sites in Texas: - Texas Oncology - Central South — Austin, Texas
- Texas Oncology - Central South — Austin, Texas
- Texas Oncology - Gulf Coast — Beaumont, Texas
- Texas Oncology - Gulf Coast — Houston, Texas
- Texas Oncology - Gulf Coast — Houston, Texas
Phase 1, Phase 2 Recruiting Industry
The main purpose of this study is to determine the safety, tolerability (how the body reacts to the drug\[s\]) and effectiveness (ability to treat the cancer) of REGN5678 (Nezastomig) alone, or in combination with cemiplimab. The study has…
Sponsor: Regeneron Pharmaceuticals
NCT ID: NCT03972657
Sites in Texas: - MD Anderson Cancer Center — Houston, Texas
Phase 1, Phase 2 Recruiting Network
This phase I/II trial evaluates the highest safe dose, side effects, and possible benefits of tegavivint in treating patients with solid tumors that has come back (recurrent) or does not respond to treatment (refractory). Tegavivint interf…
Sponsor: Children's Oncology Group
NCT ID: NCT04851119
Sites in Texas: - Baylor College of Medicine/Dan L Duncan Comprehensive Cancer Center — Houston, Texas
Phase 2 Recruiting NIH
This phase II trial studies the effects of combination therapy with bevacizumab, erlotinib, and atezolizumab in treating patients with hereditary leiomyomatosis and kidney cancer that may have spread from where it first started to nearby t…
Sponsor: National Cancer Institute (NCI)
NCT ID: NCT04981509
Sites in Texas: - M D Anderson Cancer Center — Houston, Texas
Phase 1, Phase 2 Recruiting Industry
This study is researching an experimental drug called REGN10597 alone or in combination with another drug called cemiplimab (called "study drug(s)"). The study is focused on patients with certain solid tumors that are in an advanced stage.…
Sponsor: Regeneron Pharmaceuticals
NCT ID: NCT06413680
Sites in Texas: - MD Anderson Cancer Center — Houston, Texas
- Next Oncology — San Antonio, Texas
- The Start Center for Cancer Care — San Antonio, Texas
Phase 1, Phase 2 Recruiting Industry
The purpose of this study is to assess the safety, tolerability, and recommended dose(s) of BMS-986340 as monotherapy and in combination with nivolumab or docetaxel in participants with advanced solid tumors. This study is a first-in-human…
Sponsor: Bristol-Myers Squibb
NCT ID: NCT04895709
Sites in Texas: - Houston Methodist Hospital — Houston, Texas
Phase 1, Phase 2 Recruiting Industry
This is a first in human, open-label, multi-center Phase 1 / 2 study to evaluate the safety, tolerability, and initial efficacy of AU-007 in patients with advanced solid tumors. AU-007 will be administered either as a monotherapy, or in co…
Sponsor: Aulos Bioscience, Inc.
NCT ID: NCT05267626
Sites in Texas: - Texas Oncology (Balcones) - SCRI — Austin, Texas
- MD Anderson Cancer Center — Houston, Texas
- START South Texas Accelerated Research Therapeutics — San Antonio, Texas
Phase 2 Recruiting Industry
This is a Phase 2, open-label, multicenter study designed to evaluate the efficacy, safety and tolerability of IBI363 (study drug) in subjects with advanced, refractory solid malignancies.
Sponsor: Innovent Biologics (Suzhou) Co. Ltd.
NCT ID: NCT06281678
Sites in Texas: - MD Anderson Cancer Center-University of Texas — Houston, Texas
- Oncology Consultants P.A. — Houston, Texas
Phase 1, Phase 2 Recruiting Industry
This is a Phase 1/2, multi-center, open-label, dose-escalation and expansion study to evaluate safety and tolerability, PK, pharmacodynamic, and early signal of anti-tumor activity of MDNA11 alone or in combination with a checkpoint inhibi…
Sponsor: Medicenna Therapeutics, Inc.
NCT ID: NCT05086692
Sites in Texas: - MD Anderson Cancer Center — Houston, Texas
Phase 1, Phase 2 Recruiting Academic/Other
The phase I portion of this study is designed for children or adolescents and young adults (AYA) with a diagnosis of a solid tumor that has recurred (come back after treatment) or is refractory (never completely went away). The trial will …
Sponsor: St. Jude Children's Research Hospital
NCT ID: NCT04901702
Sites in Texas: - Texas Children's Hospital/ Baylor College of Medicine — Houston, Texas
Phase 2 Recruiting Academic/Other
This phase II trial tests whether using genetic testing of tumor tissue to select the optimal treatment regimen works in treating patients with clear cell renal cell (kidney) cancer that has spread to other places in the body (advanced or …
Sponsor: Vanderbilt-Ingram Cancer Center
NCT ID: NCT05361720
Sites in Texas: - University of Texas, Southwestern Medical Center — Dallas, Texas
Phase 1, Phase 2 Recruiting Industry
This multi-site, Phase 1/2 clinical trial is an open-label study to identify the safety, pharmacokinetics, and efficacy of a repeated dose regimen of NEO212 alone for the treatment of patients with radiographically-confirmed progression of…
Sponsor: Neonc Technologies, Inc.
NCT ID: NCT06047379
Sites in Texas: - Baylor, Scott and White Research Institute — Dallas, Texas
Phase 1, Phase 2 Recruiting Industry
This study is designed to characterize the safety, tolerability, and anti-tumor activity of MDX2001 in patients with advanced solid tumors.
Sponsor: ModeX Therapeutics, An OPKO Health Company
NCT ID: NCT06239194
Sites in Texas: - MD Anderson Cancer Center — Houston, Texas
- NEXT Oncology — San Antonio, Texas
Phase 1, Phase 2 Recruiting Industry
A Study to Investigate Safety of AZD6750 in Adult Participants With Select Advanced or Metastatic Solid Tumors
Sponsor: AstraZeneca
NCT ID: NCT07115043
Sites in Texas: - Research Site — Houston, Texas
- Research Site — San Antonio, Texas
Phase 1, Phase 2 Recruiting Industry
This study is an open-label Phase Ib (Part A) dose escalation followed by a blinded, randomized, multi cohort Phase 2a (Part B) comparison of combination vs. reference regimens. Currently study will only be enrolling the Phase 1b and the P…
Sponsor: 7 Hills Pharma, LLC
NCT ID: NCT06362369
Sites in Texas: - MD Anderson Cancer Center — Houston, Texas